Povorcitinib

Phase 3

Incyte Corporation (INCY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in NonSegmental Vitiligo

Drug Information

Target Indication

NonSegmental Vitiligo

Clinical Trial

NCT06113445

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Povofortay

Treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

INCY

Incyte Corporation

Services-Commercial Physical & Biological Research•North America•NASDAQ

Related Pipeline

pembrolizumab + epacadostatPhase 3

Melanoma

INCA034176Phase 3

Chronic Graft-versus-host-disease

Ruxolitinib CreamPhase 3

Nonsegmental Vitiligo With Genital Involvement

ItacitinibPhase 3

MPN (Myeloproliferative Neoplasms)

Extracorporeal photopheresis (ECP)Phase 3

Graft-versus-host Disease (GVHD)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts